Sharon R. Lewin

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Editorial: HIV and lipopolysaccharide: double trouble in the liver.

Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?

Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.

The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.

Barriers and strategies to achieve a cure for HIV.

Strategies for an HIV cure: progress and challenges.

Functional cure of HIV: the scale of the challenge.

Between a shock and a hard place: challenges and developments in HIV latency reversal.

CD4 T cell signatures in HIV infection.

Tesamorelin, liver fat, and NAFLD in the setting of HIV.

CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained.

Limitations of dual-fluorescent HIV reporter viruses in a model of pre-activation latency.

Combination Immune Checkpoint Blockade to Reverse HIV Latency.

Kick and kill for HIV latency.

A cure for HIV: how would we know?

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.

Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting.

Leveraging the advances in HIV for COVID-19.

Multi-stakeholder consensus on a target product profile for an HIV cure.

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.

The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy.

Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study.

The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency.

Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance.

Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.

Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Immune checkpoint blockade in HIV.

Nanoscale probing and imaging of HIV-1 RNA in cells with a chimeric LNA-DNA sensor.

Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size.

Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.

Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR).

Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.

The role of latency reversal in HIV cure strategies.

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.